High occupational level is associated with poor response to the treatment of depression: A replication study.


Journal

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
ISSN: 1873-7862
Titre abrégé: Eur Neuropsychopharmacol
Pays: Netherlands
ID NLM: 9111390

Informations de publication

Date de publication:
03 2019
Historique:
received: 01 06 2018
revised: 25 09 2018
accepted: 07 01 2019
pubmed: 2 2 2019
medline: 27 8 2019
entrez: 2 2 2019
Statut: ppublish

Résumé

Major depressive disorder (MDD) is a leading cause of disability and inability to work. There is evidence that occupational factors may precipitate a MDD episode and interfere with the recovery process. In a previous investigation, we found that those employed in high occupational levels had a worse outcome after treatment for depression (Mandelli et al., 2016). The aim of the present study was to further investigate response to treatments for depression according to occupational status on an independent sample of MDD patients. Six hundred and forty-seven (647) subjects with a stable working occupation were taken from a larger independent sample of MDD patients evaluated for response and resistance to treatment for depression, after at least one adequate treatment trial. Three broad occupational categories were considered: 'manager', 'white-collar', 'blue-collar' and 'self-employed'. Managers had the highest rate of non-response and resistance to treatments. White-collar workers also had high non-response and resistance rates. At the opposite, Blue-collar workers had significantly lower rates of non-response and resistance. Self-employed were in between White- and Blue-collar workers and did not significantly differ from the other occupational categories. The findings of this replication study substantially support our previous observations. MDD patients employed in high-middle occupations may have a less favorable outcome after standard treatments of depression. Working stressful condition and other psychosocial factors at work should be investigated more closely in relation to treatment outcomes in MDD.

Identifiants

pubmed: 30704794
pii: S0924-977X(19)30107-5
doi: 10.1016/j.euroneuro.2019.01.107
pii:
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Pagination

349-355

Informations de copyright

Copyright © 2019 Elsevier B.V. and ECNP. All rights reserved.

Auteurs

Laura Mandelli (L)

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Alessandro Serretti (A)

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy. Electronic address: alessandro.serretti@unibo.it.

Daniel Souery (D)

Laboratoire de Psychologie Médicale, Université Libre de Bruxelles and PsyPluriel, Brussels, Belgium.

Julien Mendlewicz (J)

Université Libre de Bruxelles, Brussels, Belgium.

Siegfried Kasper (S)

Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.

Stuart Montgomery (S)

Imperial College, University of London, London, United Kingdom.

Joseph Zohar (J)

Expert Platform on Mental Health, Focus on Depression, Tel-Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH